Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1926
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study ; day:17 ; month:6 ; year:2016 ; pages:1-14
Clinical pharmacokinetics ; (17.6.2016), 1-14
- Urheber
- Beteiligte Personen und Organisationen
-
Stangier, Joachim
Ryn, Joanne van
Schmohl, Michael
Moschetti, Viktoria
Haazen, Wouter
Smet, Marina De
Gansser, Dietmar
Norris, Stephen
Lang, Benjamin
Reilly, Paul
Kreuzer, Jörg
SpringerLink (Online service)
- DOI
-
10.1007/s40262-016-0417-0
- URN
-
urn:nbn:de:1111-201606197396
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Glund, Stephan
- Stangier, Joachim
- Ryn, Joanne van
- Schmohl, Michael
- Moschetti, Viktoria
- Haazen, Wouter
- Smet, Marina De
- Gansser, Dietmar
- Norris, Stephen
- Lang, Benjamin
- Reilly, Paul
- Kreuzer, Jörg
- SpringerLink (Online service)
Ähnliche Objekte (12)
Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study
Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study
Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study
Idarucizumab: A novel antidote for reversal of dabigatran
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
Idarucizumab for reversal of dabigatran in early/emergency surgeries: a case series
Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study
Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study
Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study
Idarucizumab: A novel antidote for reversal of dabigatran
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
Idarucizumab for reversal of dabigatran in early/emergency surgeries: a case series
Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study
Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study
Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study
Idarucizumab: A novel antidote for reversal of dabigatran
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
Idarucizumab for reversal of dabigatran in early/emergency surgeries: a case series
Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation